Condition: Multiple Myeloma · Sponsor: Hoffmann-La Roche
This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).
This description comes directly from the study's public registry record.
Reference Study ID Number: YO43835 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Sun yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Tianjin Institute of Hematology & Blood Diseases Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, China | Recruiting |
| Tongji Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06934044